Cathie Wood’s ARK Invest Buys Over 240,000 Shares of Fate Therapeutics
A couple of Cathie Wood's ARK Invest funds bought over 240,000 shares of Fate Therapeutics on August 3.
A couple of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Tuesday. The fund bought over 240,000 shares of Fate Therapeutics Inc. (NASDAQ: FATE) altogether, as the price of these ETFs were somewhat mixed on the day. Note that these funds are up significantly in the past year.
Specifically, ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 55,163 shares of Fate Therapeutics, and ARK Innovation ETF (NYSEARCA: ARKK) bought 186,114 shares. At Tuesday’s closing price, this would have valued this purchase at roughly $20.1 million altogether. Even though this is a small fraction of the total holdings, every little bit counts. ARKG is up 50% in the past year and ARKK is up closer to 46%.
Here is a look at the other purchases across the ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | ETSY | Etsy | 90,831 |
| ARKF | HOOD | Robinhood Markets | 89,622 |
| ARKG | SRNG | Soaring Eagle Acquisition | 214,751 |
| ARKG | SMFR | Sema4 | 96,000 |
| ARKG | SGFY | Signify Health | 31,587 |
| ARKG | RPTX | Repare Therapeutics | 11,809 |
| ARKG | MASS | 908 Devices | 46,488 |
| ARKG | BEAM | Beam Therapeutics | 3,074 |
| ARKG | EDIT | Editas Medicine | 35,000 |
| ARKG | FATE | Fate Therapeutics | 55,163 |
| ARKK | VCYT | Veracyte | 16,379 |
| ARKK | PACB | Pacific Biosciences of California | 190,000 |
| ARKK | FATE | Fate Therapeutics | 186,114 |
| ARKK | BEAM | Beam Therapeutics | 37,694 |
| ARKQ | MKFG | Markforged | 397,767 |
| ARKQ | AVAV | Aerovironment | 22,232 |
| ARKW | CND | Conchord Acquisition | 3,000 |
| ARKW | KVSB | Khosla Ventures Acquisition II | 10,000 |
| ARKW | VUZI | Vuzix | 90,000 |
[nativounit]
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
[recirclink id=927148][wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
